secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2024-06-27T23:59:59+00:00
Accession:  0000950170-24-078152
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta initiates Ntrust-1 in lupus nephritis, IND cleared for 3 more autoimmune indications
--------------------------------------------------------------------------------

- First patient in screening for Ntrust-1, a trial of NKX019 in refractory lupus nephritis.
- FDA cleared IND for NKX019 in systemic sclerosis, myositis, and ANCA-associated vasculitis (Ntrust-2).
- Both trials are dose-escalation, open-label, multi-center, designed for up to 12 patients each.
- Clinical data from Ntrust-1 and Ntrust-2 expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024078152/0000950170-24-078152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024078152/nktx-20240627.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-078152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer